Aberrant Methylation of Imprinted Genes is Associated with Negative Hormone Receptor Status in Invasive Breast Cancer

Overview

Journal Int J Cancer

Specialty Oncology

Date 2015 Jan 7

PMID 25560175

Citations 18

Authors

Timothy M Barrow

Ludovic Barault

Rachel E Ellsworth

Holly R Harris

Alexandra M Binder

Allyson L Valente

Craig D Shriver

Karin B Michels

Affiliations

Soon will be listed here.

Abstract

Epigenetic regulation of imprinted genes enables monoallelic expression according to parental origin, and its disruption is implicated in many cancers and developmental disorders. The expression of hormone receptors is significant in breast cancer because they are indicators of cancer cell growth rate and determine response to endocrine therapies. We investigated the frequency of aberrant events and variation in DNA methylation at nine imprinted sites in invasive breast cancer and examined the association with estrogen and progesterone receptor status. Breast tissue and blood from patients with invasive breast cancer (n = 38) and benign breast disease (n = 30) were compared with those from healthy individuals (n = 36), matched with the cancer patients by age at diagnosis, ethnicity, body mass index, menopausal status and familial history of cancer. DNA methylation and allele-specific expression were analyzed by pyrosequencing. Tumor-specific methylation changes at IGF2 DMR2 were observed in 59% of cancer patients, IGF2 DMR0 in 38%, DIRAS3 DMR in 36%, GRB10 ICR in 23%, PEG3 DMR in 21%, MEST ICR in 19%, H19 ICR in 18%, KvDMR in 8% and SNRPN/SNURF ICR in 4%. Variation in methylation was significantly greater in breast tissue from cancer patients compared with that in healthy individuals and benign breast disease. Aberrant methylation of three or more sites was significantly associated with negative estrogen-alpha (Fisher's exact test, p = 0.02) and progesterone-A (p = 0.02) receptor status. Aberrant events and increased variation in imprinted gene DNA methylation, therefore, seem to be frequent in invasive breast cancer and are associated with negative estrogen and progesterone receptor status, without loss of monoallelic expression.

Citing Articles

Malignancies in Prader-Willi Syndrome: Results From a Large International Cohort and Literature Review.

Pellikaan K, Nguyen N, Rosenberg A, Coupaye M, Goldstone A, Hoybye C J Clin Endocrinol Metab. 2023; 108(12):e1720-e1730.

PMID: 37267430 PMC: 10655548. DOI: 10.1210/clinem/dgad312.

Comparative Analysis of Transcriptomic Changes including mRNA and microRNA Expression Induced by the Xenoestrogens Zearalenone and Bisphenol A in Human Ovarian Cells.

Marton E, Varga A, Penyige A, Birko Z, Balogh I, Nagy B Toxins (Basel). 2023; 15(2).

PMID: 36828454 PMC: 9967916. DOI: 10.3390/toxins15020140.

Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies.

Thakur C, Qiu Y, Fu Y, Bi Z, Zhang W, Ji H Front Oncol. 2022; 12:971288.

PMID: 36185256 PMC: 9520778. DOI: 10.3389/fonc.2022.971288.

Race and prostate cancer: genomic landscape.

Arenas-Gallo C, Owiredu J, Weinstein I, Lewicki P, Basourakos S, Vince Jr R Nat Rev Urol. 2022; 19(9):547-561.

PMID: 35945369 DOI: 10.1038/s41585-022-00622-0.

DNA Methylation of Imprinted Genes , , and in Peripheral Blood Is Associated with the Risk of Breast Cancer.

Fu J, Zhang L, Li D, Tian T, Wang X, Sun H Cancers (Basel). 2022; 14(11).

PMID: 35681632 PMC: 9179312. DOI: 10.3390/cancers14112652.

References

Dowdy S, Gostout B, Shridhar V, Wu X, Smith D, Podratz K . Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecol Oncol. 2005; 99(1):126-34. DOI: 10.1016/j.ygyno.2005.05.036. View

Li Y, Meng G, Guo Q . Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. Exp Mol Pathol. 2008; 84(3):234-9. DOI: 10.1016/j.yexmp.2008.03.013. View

Fackler M, Umbricht C, Williams D, Argani P, Cruz L, Merino V . Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res. 2011; 71(19):6195-207. PMC: 3308629. DOI: 10.1158/0008-5472.CAN-11-1630. View

Li L, Lee K, Han W, Choi J, Lee J, Kang G . Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. Hum Mol Genet. 2010; 19(21):4273-7. DOI: 10.1093/hmg/ddq351. View

Foulkes W, Smith I, Reis-Filho J . Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48. DOI: 10.1056/NEJMra1001389. View

Heaphy C, Bisoffi M, Fordyce C, Haaland C, Hines W, Joste N . Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer. 2006; 119(1):108-16. DOI: 10.1002/ijc.21815. View

Ito Y, Koessler T, Ibrahim A, Rai S, Vowler S, Abu-Amero S . Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet. 2008; 17(17):2633-43. PMC: 2515372. DOI: 10.1093/hmg/ddn163. View

Kondo M, Suzuki H, Ueda R, Osada H, Takagi K, Takahashi T . Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene. 1995; 10(6):1193-8. View

Bediaga N, Acha-Sagredo A, Guerra I, Viguri A, Albaina C, Ruiz Diaz I . DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res. 2010; 12(5):R77. PMC: 3096970. DOI: 10.1186/bcr2721. View

10.

Guo L, Choufani S, Ferreira J, Smith A, Chitayat D, Shuman C . Altered gene expression and methylation of the human chromosome 11 imprinted region in small for gestational age (SGA) placentae. Dev Biol. 2008; 320(1):79-91. DOI: 10.1016/j.ydbio.2008.04.025. View

11.

Blagitko N, Mergenthaler S, Schulz U, Wollmann H, Craigen W, Eggermann T . Human GRB10 is imprinted and expressed from the paternal and maternal allele in a highly tissue- and isoform-specific fashion. Hum Mol Genet. 2000; 9(11):1587-95. DOI: 10.1093/hmg/9.11.1587. View

12.

Shi J, Li X, Si X, Li A, Ding H, Han X . ERα positively regulated DNMT1 expression by binding to the gene promoter region in human breast cancer MCF-7 cells. Biochem Biophys Res Commun. 2012; 427(1):47-53. DOI: 10.1016/j.bbrc.2012.08.144. View

13.

Lin D, Cui F, Bu Q, Yan C . The expression and clinical significance of GTP-binding RAS-like 3 (ARHI) and microRNA 221 and 222 in prostate cancer. J Int Med Res. 2011; 39(5):1870-5. DOI: 10.1177/147323001103900530. View

14.

Cui M, Wen Z, Yang Z, Chen J, Wang F . Estrogen regulates DNA methyltransferase 3B expression in Ishikawa endometrial adenocarcinoma cells. Mol Biol Rep. 2008; 36(8):2201-7. DOI: 10.1007/s11033-008-9435-9. View

15.

Cerrato F, Sparago A, Verde G, De Crescenzo A, Citro V, Cubellis M . Different mechanisms cause imprinting defects at the IGF2/H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumour. Hum Mol Genet. 2008; 17(10):1427-35. DOI: 10.1093/hmg/ddn031. View

16.

Teschendorff A, Jones A, Fiegl H, Sargent A, Zhuang J, Kitchener H . Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med. 2012; 4(3):24. PMC: 3446274. DOI: 10.1186/gm323. View

17.

Zhang X, Zhang L, Feng Y, Chen B, Feng Y, Liang G . Bisphenol A exposure modifies DNA methylation of imprint genes in mouse fetal germ cells. Mol Biol Rep. 2012; 39(9):8621-8. DOI: 10.1007/s11033-012-1716-7. View

18.

Pedersen I, Dervan P, Broderick D, Harrison M, Miller N, Delany E . Frequent loss of imprinting of PEG1/MEST in invasive breast cancer. Cancer Res. 1999; 59(21):5449-51. View

19.

Bentzon N, During M, Rasmussen B, Mouridsen H, Kroman N . Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer. 2007; 122(5):1089-94. DOI: 10.1002/ijc.22892. View

20.

Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U . Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One. 2008; 3(7):e2656. PMC: 2442168. DOI: 10.1371/journal.pone.0002656. View